|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
<b>Conclusion:</b> Overall, our data show that targeting PI3K/mTOR by XL765 is a promising therapeutic strategy to relieve tumor burden in GBM patients.
|
31360067 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
<i>In vitro</i> cell experiments revealed that the PI3K activity was enhanced and the PI3K/Akt pathway was significantly activated after HP infection in tumor cells, thus promoting the proliferation of tumor cells (p<0.05) in a time-dependent manner.
|
30344716 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
<i>In vivo</i> screening using PI3K inhibitors in 12 of these models identified <i>PIK3CA</i> mutation as a predictive biomarker of response (<20% tumor growth compared with baseline/vehicle).
|
30093452 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
<i>In vivo</i> study, the weight of tumour tissues at deoxyshikonin groups was significantly reduced compared with the control group, and PI3K, p-PI3K, Akt, p-Akt308 and mTOR expression was decreased.
|
31230505 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
<i>PTEN</i> is a tumor suppressor gene that classically dampens the PI3K/AKT/mTOR growth-promoting signaling cascade.
|
31433956 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
15-Deoxy-Δ<sup>12,14</sup>-prostaglandin J<sub>2</sub> activates PI3K-Akt signaling in human breast cancer cells through covalent modification of the tumor suppressor PTEN at cysteine 136.
|
29550515 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Tumor cell killing correlates with regulation of proteins involved in the Wnt and PI3K pathways: beta-catenin, APC, GSK-3, JNK, and PTEN.
|
15851011 |
2005 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Tumor genetic analyses have revealed that the signaling pathways regulated by PI3K and RAS are of fundamental importance in a wide variety of human neoplasms, leading to intensive efforts to develop therapeutics that block signaling through these two key pathways.
|
20014924 |
2010 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Tumor DNA was isolated for sequence analysis of TP53 (exons 4 to 8), hotspot mutation analysis of KRAS (exon 1) and PI3K (exon 9 and 20) and microsatellite-instability (MSI) analysis including MLH1 promotor-methylation status.
|
22609107 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Tumor growth inhibition in mice was accompanied by a significant reduction of phosphorylated Akt (pAKT) (S473), a well-established surrogate biomarker of PI3K/mTOR signaling pathway inhibition.
|
23826249 |
2013 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Tumors that developed in the absence of ERBB3 remained sensitive to EGFR tyrosine kinase inhibitors and retained activation of the PI3K-AKT pathway.
|
25596284 |
2015 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Tumor tissue showed moderate inhibition of PI3K and mitogen-activated protein kinase (MAPK) pathways.
|
28275119 |
2017 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Tumors with low P120CTN and PI3K pathway mutations have higher levels of MMP1 compared to tumors with high P120CTN and no PI3K pathway mutations.
|
28637905 |
2017 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Tumor types that frequently harbored at least 1 PI3K alteration were uterine (77%), cervical (62%), anal (59%), and breast (58%) cancers.
|
30582752 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Tumor incidence was markedly lower in fisetin-treated FC<sup>1</sup> 3K<sup>1</sup> Apc<sup>Min/+</sup> mice that also express constitutively active PI3K in distal small intestine and colon, as compared to control animals, indicating that fisetin is a strong preventive agent.
|
31018249 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
PI3K activation occurred early in prostate intraepithelial neoplasia lesion formation in these animals, consistent with loss of PTEN function, and contributed to the etiology of tumors that developed in Pten(+/-) mice.
|
19395652 |
2009 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
PI3K pathway activation was significantly associated with ER negative (p = 0.0008) and PR negative (p = 0.006) status, high tumor grade (p = 0.032) and a "basal-like" phenotype (p = 0.01), where 92% (25/27) of tumors had an altered pathway.
|
19685490 |
2010 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
PI3K pathway inhibitors are currently being evaluated in patients with tumors in which the PI3K pathway is deregulated.
|
21903247 |
2011 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
PI3K pathway mutations co-occurred with BRAF(V600) mutations in 17% of the tumors and co-occurred with 9% of NRAS mutant tumors, implying cooperativity between these pathways in terms of melanoma progression.
|
22912864 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
PI3K/MMPs/Ln-5γ2 and EphA2/FAK/Paxillin as key signaling pathways in a coordinated manner contributed to tumor growth and VM of gallbladder carcinomas and provided novel targets that could be potentially exploited for therapeutic intervention of human gallbladder carcinomas.
|
23588386 |
2013 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
PI3K pathway-mutated HNSCC tumors harbored a significantly higher rate of mutations in known cancer genes.
|
23619167 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
PI3K-mTOR inhibition can enhance TP53/p73 expression and significantly inhibit tumor growth alone or when combined with radiation in HNSCC with wild-type TP53.
|
23640975 |
2013 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
PI3K pathway-mutated tumors showed a trend toward poorer DFS (P = 0.06) following cetuximab (8/22) as compared with those following standard treatment only (6/18).
|
25724520 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
PI3Kγ synergizes with checkpoint inhibitor therapy to promote tumour regression and increased survival in mouse models of cancer.
|
27642729 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
PI3K/Akt/mTOR signaling & its regulator tumour suppressor genes <i>PTEN</i> & <i>LKB1</i> in human uterine leiomyomas.
|
27748285 |
2016 |